IPO Success Strengthens Clinical Execution Capabilities

Attovia Therapeutics (ATTO) successfully raised $289 million through an initial public offering (IPO) of 17 million shares at $17 per share. The increased IPO size demonstrates that even companies in the Phase 1 stage can attract significant institutional investment if they possess a differentiated mechanism of action and a promising pipeline in the field of immune diseases. However, it is important to note that this figure represents the total amount raised, and the net proceeds after deducting underwriting fees and expenses will be lower. The key takeaway is that the secured funding will enhance Attovia's financial capacity to simultaneously advance the Phase 2 trial of ATTO-1310 and initiate clinical trials for ATTO-2306 and ATTO-1091.

ATTO-1310, an IL-31 Ligand Blocker, is Preparing for Phase 2 Trials

ATTO-1310, a half-life extended ATTOBODY-based biologic that binds to the IL-31 ligand, is in development. Clinical trials involving both healthy individuals and patients were completed in the first quarter of 2026, and a Phase 2 trial targeting chronic unexplained pruritus (CPUO) and severe pruritus associated with atopic dermatitis is scheduled to begin in the first half of 2027. The U.S. market for chronic pruritus patients is projected to exceed 15 million by 2035, making patient selection and the speed of itch reduction critical factors for commercial success. In the Phase 2 trial, both safety and the magnitude and duration of improvement in the pruritus numerical rating scale will be key evaluation metrics.

Competition with Nemluvio and Dupixent Based on Mechanism and Convenience

The primary competitor is Nemluvio (nemolizumab-ilto, an IL-31 receptor alpha antagonist) from Galderma Group AG (GALD). Nemluvio was approved by the FDA on August 12, 2024, for nodular prurigo and in December 2024 for the treatment of moderate-to-severe atopic dermatitis, and received EMA approval on February 12, 2025. Dupixent (dupilumab, an IL-4Rα inhibitor), a standard biologic therapy, is marketed by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) and generated $17.8 billion in sales in 2025. Atovia highlights its differentiation by directly blocking the IL-31 ligand rather than the receptor; however, whether this approach will result in faster or more potent clinical effects remains to be demonstrated through comparative patient data.

A Multi-Specific Pipeline as the Second Pillar of Corporate Value

The pre-clinical candidate ATTO-2306 is a bispecific protein that simultaneously inhibits IL-13 and IL-31, and a Phase 1 trial is scheduled to begin in the first half of 2027. The number of atopic dermatitis patients in the U.S. is projected to reach 21 million adults and 10 million children by 2035, and the global market for atopic dermatitis drugs was approximately $21 billion in 2025. ATTO-1091 is a trispecific Fc fusion protein targeting TL1A, IL-23, and integrin α4β7 for the treatment of inflammatory bowel disease, and is also targeted for Phase 1 trial initiation in the first half of 2027. The underlying ATTOBODY technology was licensed from Alamar Biosciences, and the agreement includes clinical and regulatory milestone payments of up to $4.3 million per product, as well as low single-digit royalties based on net sales.